Smart Back-to-School Policy: Cell Phone Bans with a Medical Exception
Thousands of K-12 students returning to school this fall will face a cell phone use ban during instructional hours. Diabetes monitoring deserves an exception.
Government & Legislative Affairs
Learn more about our Advocacy work.
AdvaMed®, Patient Groups, State Medtech Associations Urge Medicare Coverage of Breakthrough Medtech
WASHINGTON, D.C.—AdvaMed, the MedTech Association®, is among 67 stakeholder groups, including patient advocacy groups and state medtech and life sciences associations, urging the Centers for Medicare and Medicaid Services (CMS)…
Scott Whitaker Op-Ed: Medtech is vital to a healthier America
A powerful op-ed from AdvaMed’s CEO explaining why tariffs could undermine U.S. medtech innovation, jobs, and patient care—and what must be done.
AdvaMed® Welcomes MDUFA VI Discussion Kickoff at FDA Public Meeting
WASHINGTON, D.C.—AdvaMed, the MedTech Association®, today welcomed the kickoff of the latest Medical Device User Fee Amendments (MDUFA) discussion at a public meeting at FDA headquarters. ThreeAdvaMed® senior staff members…
AdvaMed® Welcomes Administration’s Health Data Sharing Pledge
AdvaMed, the MedTech Association®, released the following statement today from Shaye Mandle, executive director of the organization’s Digital Health Tech division, on the announcement from the White House, CMS, and…
ICYMI:AdvaMed® Op-ed on the Vital Role of Medtech in Making Americans Healthy Again
WASHINGTON, D.C. – In a new op-ed in The Washington Times, Scott Whitaker, president and CEO of AdvaMed, the MedTech Association®, laid out medtech’s vital role in the Trump administration’s…
AdvaMed® Welcomes White House’s “America’s AI Action Plan”
WASHINGTON, D.C.—Scott Whitaker, president and CEO of AdvaMed, the MedTech Association®, issued the following statement on the White House’s “America’s AI Action Plan”:
AdvaMed® Advancements: Q2 2025 Report
Discover our Q2 report highlighting key industry wins, tariff updates, and strategic progress driving medtech innovation and advocacy forward.
AdvaMed® Comments to HHS Deregulation RFI
AdvaMed® submitted public comments in response to HHS’s request for information on eliminating federal regulations that hinder economic growth, innovation, and American competitiveness.
The Kennedy v Braidwood Ruling: What’s Next for MedTech
JoinAdvaMed® and Reed Smith experts to explore how the Supreme Court’s ACA ruling in Braidwood could shape preventive care and MedTech policy.